| | Business Summary | | Genzyme
Transgenics
Corporation
(GTC)
is
engaged
in
the
application
of
transgenic
technology
to
the
development
and
production
of
recombinant
proteins
for
therapeutic
and
other
biomedical
uses.
To
date,
GTC
has
produced
more
than
65
such
proteins,
45
through
collaborations
with
various
commercial
and
academic
organizations
and
20
independently.
More
than
half
of
the
transgenic
proteins
actively
under
development
by
the
Company
are
monoclonal
antibodies
(MAB)
or
immunoglobulin
(Ig)
fusion
proteins. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | GZTC
is
engaged
in
the
application
of
transgenic
technology
to
the
development
and
production
of
genetically
engineered
proteins
for
the
therapeutic,
diagnostic
and
other
biomedical
uses.
For
the
six
months
ended
7/1/01,
revenues
decreased
33%
to
$5.2
million.
Net
loss
from
continuing
operations
applicable
to
Common
totaled
$12.7
million,
up
from
$6
million.
Revenues
reflect
the
absence
of
milestones
earned.
Net
loss
also
reflects
higher
R&D
expenses
due
to
increased
activity. | | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Geoffrey Cox, Ph.D.
Chairman,
CEO | -- | -- | John Green, 47
CFO,
VP-Fin., Treasurer | $291K | $849K | Henry Meade, 54
VP
of Transgenics Research | 235K | 1.4M | Michael Young, 49
VP,
Commercial Devel. | 247K | 903K | | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/g/gztc.gif)